Intelligence Feed event · Macro · 2026-08-04

    Supernus Pharmaceuticals to Merge with Indivior in All-Stock Deal

    Question

    Supernus Pharmaceuticals to Merge with Indivior in All-Stock Deal

    Direct answer

    The deal aims to scale the combined company's commercial footprint in CNS and specialty therapeutics. While the stock rose 3%, initial gains were higher, suggesting market skepticism regarding the valuation or the timeline for synergy realization. Law firms have already initiated investigations into the fairness of the deal for SUPN shareholders, a standard post-announcement friction.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Supernus Pharmaceuticals to Merge with Indivior in All-Stock Deal”, revision 1, evidence through 2026-08-04. https://marketontology.com/market-events/2026-08-04/supernus-pharmaceuticals-to-merge-with-indivior-in-all-stock-deal-9f2e0e

    MACRO
    Supernus Pharmaceuticals to Merge with Indivior in All-Stock Deal
    The deal aims to scale the combined company's commercial footprint in CNS and specialty therapeutics. While the stock rose 3%, initial gains were higher, suggesting market skepticism regarding the valuation or the timeline for synergy realization. Law firms have already initiated investigations into the fairness of the deal for SUPN shareholders, a standard post-announcement friction.
    SUPN
    Impact
    74
    AUG 4
    SIG
    90%
    SUPN
    Supernus Pharmaceuticals to Merge with Indivior in All-Stock Deal
    The deal aims to scale the combined company's commercial footprint in CNS and specialty therapeutics. While the stock rose 3%, initial gains were higher, suggesting market skepticism regarding the valuation or the timeline for synergy realization. Law firms have already initiated investigations into the fairness of the deal for SUPN shareholders, a standard post-announcement friction.
    → Sector consolidation and synergy realization in mid-cap pharma.
    Impact
    The deal aims to scale the combined company's commercial footprint in CNS and specialty therapeutics. While the stock rose 3%, initial gains were higher, suggesting market skepticism regarding the valuation or the timeline for synergy realization. Law firms have already initiated investigations into the fairness of the deal for SUPN shareholders, a standard post-announcement friction.
    Affected
    SUPN
    Transmission
    Sector consolidation and synergy realization in mid-cap pharma.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month